Download Files:
Rebastinib
SKU
HY-13024-10 mg
Category Reference compound
Tags Apoptosis;Bcr-Abl;FLT3;Src, Apoptosis;Protein Tyrosine Kinase/RTK, Cancer
$77 – $319
Products Details
Product Description
– Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
Web ID
– HY-13024
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C30H28FN7O3
References
– [1]Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19(4), 556-568.
CAS Number
– 1020172-07-9
Molecular Weight
– 553.59
Compound Purity
– 99.91
SMILES
– CC(C)(C)C1=NN(C(NC(NC2=C(F)C=C(OC3=CC(C(NC)=O)=NC=C3)C=C2)=O)=C1)C4=CC=C5C(C=CC=N5)=C4
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 80°C)
Target
– Apoptosis;Bcr-Abl;FLT3;Src
Pathway
– Apoptosis;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.